Are Shrooms Legal in New York? 2026 Psilocybin Law Guide

Psilocybin, the active compound in "magic mushrooms," remains a Schedule I controlled substance under both federal and New York State law. Despite growing national interest in psychedelic therapy research, possession, sale, and use of psilocybin mushrooms remain illegal in New York.

Current Legal Status in New York

Under New York Penal Law Article 220, psilocybin mushrooms are classified as hallucinogenic substances, making their possession, cultivation, distribution, or use a criminal offense. New York has not decriminalized or legalized psilocybin for recreational or therapeutic use as of 2026.

Federal vs. State Classification

The U.S. Drug Enforcement Administration (DEA) classifies psilocybin as a Schedule I substance, indicating:

• High potential for abuse
• No currently accepted medical use in treatment in the United States
• Lack of accepted safety for use under medical supervision

New York State follows this federal classification, though research into therapeutic applications continues through institutions like NYU Langone Health.

No. New York City has not independently legalized psilocybin mushrooms. New York State controlled- substance laws continue to apply throughout all five boroughs, and there is no lawful recreational psilocybin retail or delivery market in NYC.

This applies to Manhattan, Brooklyn, Queens, the Bronx and Staten Island. Online availability, storefront sales, or social-media offers do not establish that a product is legal — possession, sale, cultivation and delivery of psilocybin remain criminal offenses under New York Penal Law Article 220.

Certain circumstances can result in more severe charges and penalties:

School Zone Enhancement

Possession or sale within 1,000 feet of a school grounds can trigger enhanced charges under NY Penal Law § 220.44.

Prior Convictions

Previous drug convictions can result in predicate felony sentencing, leading to mandatory minimum sentences and longer prison terms.

Sale to Minors

Selling or providing psilocybin to individuals under 18 carries significantly enhanced penalties and potential child endangerment charges.

Psilocybin mushroom spores may not contain psilocybin before germination, but that does not make cultivation lawful. Germinating spores, producing mycelium, or using spores to grow psilocybin-containing mushrooms can create criminal exposure under New York law.

Why the Spore Question Is Nuanced

Spores are reproductive cells and, before germination, generally do not themselves contain psilocybin or psilocin. A small number of states — including California, Idaho and Georgia — have explicitly banned spore possession. New York has not enacted a standalone spore ban, but that is not the same thing as saying spores are broadly “legal.”

Where the Law Draws the Line

Once spores germinate into mycelium — and especially once mycelium fruits mushrooms containing psilocybin — the material is a Schedule I controlled substance. Growing, propagating or processing that material can be charged as manufacturing a controlled substance, which is a felony.

Is Psilocybin Mycelium Legal?

The legal treatment of mycelium depends on its contents and surrounding circumstances. Mycelium associated with psilocybin cultivation — particularly when found with substrate, grow bags, dried mushrooms or cultivation equipment — can create substantial legal risk, including intent-to-manufacture charges.

Microdosing psilocybin is not legal in New York. State law does not create a personal-use, therapeutic-use, or low-dose exception for possessing psilocybin outside an authorized research setting.

No Minimum Quantity Exception

New York's controlled substance laws do not distinguish between a microdose and a full dose. Any measurable amount of psilocybin constitutes criminal possession under Penal Law § 220.03. A person found with capsules containing 0.1 grams faces the same charges as someone possessing several grams.

Growing Trend, Zero Legal Protection

While interest in microdosing has grown significantly — driven by research from institutions like Johns Hopkins Center for Psychedelic & Consciousness Research — New York offers no legal framework for this practice. Unlike Oregon, which has created a regulated therapeutic pathway, New York has not introduced any legislation to accommodate microdosing.

If you or someone you know is struggling with substance use, including the use of psychedelics, professional support is available. Contact our helpline at (844) 338-6969 for confidential guidance on treatment options.

Chocolate, gummies, capsules and other edible formats do not make psilocybin lawful. The controlling issue is whether the product contains psilocybin, psilocin, or another prohibited substance — not the form it is sold in.

Some “mushroom” chocolate bars and gummies sold in smoke shops or online do not contain psilocybin at all, and instead include other unregulated compounds. Others do contain psilocybin or related tryptamines. Professional packaging, brand labels, and social-media marketing are not proof of legality. If the product contains a controlled substance, possession, sale and delivery are illegal under New York law.

Several states and jurisdictions have moved to decriminalize or regulate psilocybin. New York has not taken any similar action. Here is how the state compares:

New York residents who travel to Oregon or Colorado to participate in legal psilocybin programs should be aware that returning to New York with any psilocybin product remains a criminal offense under NY law.

Common defense strategies in psilocybin cases include:

Constitutional Defenses

• Illegal Search and Seizure: Evidence obtained in violation of Fourth Amendment rights may be suppressed
• Lack of Probable Cause: Challenging the legality of the initial stop or arrest
• Chain of Custody Issues: Questioning proper handling of evidence

Factual Defenses

• Lack of Knowledge: Defendant was unaware of the presence of psilocybin
• Constructive Possession: Challenging whether defendant had control over the substance
• Misidentification: Questioning whether the substance is actually psilocybin

Treatment Court Alternatives

New York's Drug Treatment Courts may offer alternatives to incarceration:

• Intensive supervision and monitoring
• Mandatory substance abuse treatment
• Regular court appearances
• Potential for charge reduction or dismissal upon successful completion

Legalization permits specified conduct under law. Decriminalization generally reduces penalties or enforcement priority without creating a lawful commercial market. New York has not enacted statewide psilocybin legalization or broad statewide decriminalization.

• Legalization — the activity is permitted and typically regulated (Oregon Measure 109 supervised service centers are an example).
• Decriminalization — penalties for specific conduct are reduced or removed, but a legal commercial market is not created (Colorado Proposition 122 for personal use).
• Enforcement deprioritization — a local jurisdiction directs its police or prosecutors to treat the offense as low priority; the underlying state law still applies (Washington, DC Initiative 81 is often cited).
• Medical or supervised access — a narrow, regulated pathway for supervised use, typically limited to specific conditions or trained facilitators.

None of these categories currently apply to psilocybin in New York State. Possession, cultivation, sale and delivery remain criminal offenses.

A pending bill is not current law. Even if a bill has been introduced, it does not change what is legal in New York until it is passed by both chambers and signed by the Governor.

Verification: Bill status last verified July 17, 2026 against the New York State Senate bill tracker. Status may change; check the linked bill page for the current position.

Even if A2142A or a similar bill were to pass, it would not authorize recreational possession, retail sales, or personal cultivation of psilocybin mushrooms. Until legislation is enacted, existing controlled-substance offenses continue to apply.

Research and Therapeutic Use

Although recreational psilocybin remains illegal in New York, scientific research into its potential therapeutic uses continues to expand. Researchers are studying psilocybin-assisted therapy for conditions including treatment-resistant depression, major depressive disorder, post-traumatic stress disorder (PTSD), substance use disorders, anxiety associated with life-threatening illness, and obsessive-compulsive disorder. While early clinical studies have shown promising results, psilocybin has not been approved by the U.S. Food and Drug Administration (FDA) for the treatment of depression or any other medical condition. Several investigational psilocybin-assisted therapies have received FDA Breakthrough Therapy designation, a program designed to accelerate development and review of promising treatments for serious conditions. Breakthrough Therapy designation does not mean a drug has been approved or is legally available outside approved research settings. The most advanced investigational program, Compass Pathways' COMP360 for treatment-resistant depression, has reported positive Phase 3 clinical trial results. Readers should consult the sponsor's latest public updates because regulatory timelines and development milestones may change. Status last verified: July 17, 2026.

Understanding FDA Approval vs. Breakthrough Therapy

FDA approval and Breakthrough Therapy designation are different regulatory milestones. For example, Zurzuvae (zuranolone), approved by the FDA in August 2023 as the first oral treatment for postpartum depression, went through full approval involving clinical trials, FDA review, and an approved label. Psilocybin has not received FDA approval. Breakthrough Therapy designation provides an expedited development pathway; it does not establish that psilocybin is safe, effective, approved, or legally available for routine medical treatment.

Decriminalization Efforts

Several jurisdictions nationwide have decriminalized psilocybin, though New York State has not yet passed similar legislation. Monitor updates from:

• New York State Senate
• New York State Assembly
• NYS Office of Addiction Services and Supports (OASAS)

Advocacy groups continue to push for reform similar to measures passed in Oregon, Colorado, and some California cities.

What This Means for New York Residents

Even if clinical research continues to produce positive results, New York law does not currently authorize recreational psilocybin use, and FDA approval would not automatically change state criminal laws governing possession, cultivation, manufacture, or distribution. Any future change would require action by federal regulators, the New York Legislature, or both.